{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:20:08Z","timestamp":1792808408717,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,12,13]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>While microsatellite instability-high (MSI-H) colorectal cancer (CRC) exhibits high sensitivity to immunotherapy, microsatellite stable (MSS) CRC is a particularly immune-resistant disease. Whether microsatellite status remains unvaried in solid tumours or changes over time under treatment pressure is largely unknown, as, to our knowledge, no previous cases have been reported in the literature.<\/jats:p>\n                  <jats:p>Here, we report the case of a patient with MSI-H CRC who experienced a long-lasting complete response to first-line pembrolizumab, but subsequently relapsed after more than 4 years with an MSS phenotype, which acts as an immune escape mechanism. This case may present new challenges in this field that have not been previously described.<\/jats:p>","DOI":"10.1136\/bcr-2024-264115","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:35:16Z","timestamp":1767180916000},"page":"e264115","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Change in MMR status as a mechanism of acquired resistance to immunotherapy in a dMMR colorectal cancer"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3659-4800","authenticated-orcid":false,"given":"Giovanni","family":"Farinea","sequence":"first","affiliation":[{"name":"Oncology Department, University of Turin, Torino, Torino, Italy"},{"name":"Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Ant\u00f3n-Pascual","sequence":"additional","affiliation":[{"name":"Oncology Department, Ramon y Cajal University Hospital Medical Oncology Service, Madrid, Comunidad de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Catoya Villa","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Riesco-Martinez","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2025123106150425000_18.12.e264115.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00495-z"},{"key":"2025123106150425000_18.12.e264115.2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3870"},{"key":"2025123106150425000_18.12.e264115.3","first-page":"735","article-title":"Microsatellite Instability in Colorectal Cancer: Overview of Its Clinical Significance and Novel Perspectives","volume":"16","author":"Battaglin","year":"2018","journal-title":"Clin Adv Hematol Oncol HO"},{"key":"2025123106150425000_18.12.e264115.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00253","article-title":"Outcomes of Chemotherapy for Microsatellite Instable-High Metastatic Colorectal Cancers","volume":"2","author":"Shulman","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025123106150425000_18.12.e264115.5","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2018.36.15_suppl.3591","article-title":"Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306)","volume":"36","author":"Heinemann","year":"2018","journal-title":"JCO"},{"key":"2025123106150425000_18.12.e264115.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x"},{"key":"2025123106150425000_18.12.e264115.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008"},{"key":"2025123106150425000_18.12.e264115.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2025123106150425000_18.12.e264115.9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174245","article-title":"Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers","volume":"15","author":"Ros","year":"2023","journal-title":"Cancers"},{"key":"2025123106150425000_18.12.e264115.10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","article-title":"Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms","volume":"121","author":"Sahin","year":"2019","journal-title":"Br J Cancer"},{"key":"2025123106150425000_18.12.e264115.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01464"},{"key":"2025123106150425000_18.12.e264115.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02446"},{"key":"2025123106150425000_18.12.e264115.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766"},{"key":"2025123106150425000_18.12.e264115.14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30027-0"},{"key":"2025123106150425000_18.12.e264115.15","first-page":"1","article-title":"Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues","volume":"42","author":"Sahin","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025123106150425000_18.12.e264115.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3967"},{"key":"2025123106150425000_18.12.e264115.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00369","article-title":"Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer","volume":"11","author":"Picard","year":"2020","journal-title":"Front Immunol"},{"key":"2025123106150425000_18.12.e264115.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103434"},{"key":"2025123106150425000_18.12.e264115.19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11912-022-01241-z","article-title":"Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review","volume":"24","author":"Plazy","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"2025123106150425000_18.12.e264115.20","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.modpat.2022.100012","article-title":"Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features","volume":"36","author":"Berrino","year":"2023","journal-title":"Mod Pathol"},{"key":"2025123106150425000_18.12.e264115.21","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0788-5","article-title":"Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI\/dMMR status","volume":"7","author":"Loupakis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025123106150425000_18.12.e264115.22","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2007.060162"},{"key":"2025123106150425000_18.12.e264115.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01777-9"},{"key":"2025123106150425000_18.12.e264115.24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ccell.2022.12.003","article-title":"Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance","volume":"41","author":"Amodio","year":"2023","journal-title":"Cancer Cell"},{"key":"2025123106150425000_18.12.e264115.25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7308"},{"key":"2025123106150425000_18.12.e264115.26","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001089"},{"key":"2025123106150425000_18.12.e264115.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.03.029"},{"key":"2025123106150425000_18.12.e264115.28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"2025123106150425000_18.12.e264115.29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025123106150425000_18.12.e264115.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01886-0"},{"key":"2025123106150425000_18.12.e264115.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50026-4","article-title":"Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy","volume":"15","author":"Osumi","year":"2024","journal-title":"Nat Commun"},{"key":"2025123106150425000_18.12.e264115.32","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00031","article-title":"Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient","volume":"8","author":"Wu","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2025123106150425000_18.12.e264115.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00710-4"},{"key":"2025123106150425000_18.12.e264115.34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235822","article-title":"Transforming Growth Factor-\u03b2 Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment","volume":"20","author":"Itatani","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025123106150425000_18.12.e264115.35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","article-title":"Wnt signaling pathway in cancer immunotherapy","volume":"525","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"2025123106150425000_18.12.e264115.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1726"},{"key":"2025123106150425000_18.12.e264115.37","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-264115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:15:19Z","timestamp":1767190519000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-264115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,31]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bcr-2024-264115"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-264115","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}